Keywords
COVID-19, Hydroxychloroquine, N-Acetylcysteine
This article is included in the Emerging Diseases and Outbreaks gateway.
This article is included in the Coronavirus collection.
COVID-19, Hydroxychloroquine, N-Acetylcysteine
The outbreak of pneumonia in Wuhan, China has been correlated with a novel coronavirus, COVID-19, isolated in January 20201. Human to human transmission has reached pandemic levels with cases infecting millions of individuals resulting in significant morbidity and mortality. Although multiple therapies have been proposed against the COVID-19 virus, no clear consensus exists on the best approach for treatment2,3.
The human body requires an efficient innate immune system in the airway mucosa to respond to viral or bacterial antigens and preserve tissue homeostasis. COVID-19 enters the human airway in a process reminiscent of other viruses4,5. The virus invades healthy cells, replicates, and leads to cellular necrosis6. Neutrophils are essential for a proper innate response to antigens derived from cellular necrosis7. We previously demonstrated that restoring the capacity of the innate immune system by modulating neutrophil activity with hydroxychloroquine (HCQ) and N-acetylcysteine (NAC) was sufficient to ameliorate local tissue effects of cellular necrosis and inflammation7 HCQ is a well-known therapy for certain inflammatory autoimmune diseases such as rheumatoid arthritis and lupus erythematosus and has significant impact on Toll-like receptor 9 (TLR-9) activity8. NAC has been used as an antioxidant, as a modulator of inflammatory responses due to its actions on NF-κβ9, as a mucolytic agent, and for the treatment of acetaminophen-induced liver failure10. In a patient with COVID-19 infection, we used oral low-dose HCQ in combination with intravenous NAC in an effort to modulate the inflammatory response secondary to COVID-19.
We describe a 54-year-old Caucasian male patient, with past medical history significant for hypertension, hyperlipidemia, and obesity, who tested positive for COVID-19 by reverse-transcriptase-polymerase-chain-reaction (RT-PCR) 11 days prior to his admission on mid April, 2020 (Table 1) at Holy Family Hospital in Methuen, Massachusetts. Upon presentation, he was admitted to the Intensive Care Unit with shortness of breath, body aches, fever, diaphoresis, tachypnea, low oxygen saturation of 92% requiring oxygen supplementation via non-rebreather mask, elevated lactic acid of 7.6 (0.5–2.2 mmol/L), and hyperglycemia with blood glucose of 402 (<100 mg/dL fasting). His vital signs included initial blood pressure of 92/62 mmHg (72 MAP), respiratory rate of 48 bpm, heart rate 120-130 bpm, and temperature of 97°F.
Initial laboratory work-up showed elevations of inflammatory markers common to patients diagnosed with COVID-197–9 (Table 2); particularly lymphocytes 900 (850-3900 cells per mm3), high-sensitivity C-reactive protein 149.2 (1.0–3.0mg/L), D-dimer 16.47 (<0.5 μg/ml FEU), lactate dehydrogenase 1579 (102–266 U/L), and serum ferritin 23713 (30–400 ng/L). A noticeable decrease in lactic acid 7.6 to 2.4 (0.5–2.2 mmol/L) was observed in the first 24 hours of treatment. He also showed signs of multi-system end-organ damage, as evidenced by elevations in alanine aminotransferase 1017 (14–63 U/L), aspartate amino transferase 852 (15–41 U/L), and serum creatinine 1.4 (0.6–1.4 mg/dL). At presentation, lung auscultation was remarkable for scattered rales, chest radiograph was unremarkable, and abdominal exam was normal.
Characteristic | Day 0* | Day 1 | Day 3 | Day 5 | Day 6 | Day 10 |
---|---|---|---|---|---|---|
White cell count (per mm3) | 17600 | 17900 | 18100 | 14600 | 12300 | 6400 |
Differential count (per mm3) | ||||||
Total neutrophils | 15000 | 14700 | 15800 | 12300 | 9900 | 4000 |
Total lymphocytes | 900 | 2000 | 1100 | 1300 | 1400 | 1700 |
Total monocytes | 900 | 1000 | 1000 | 700 | 700 | 600 |
Platelet count (per mm3) | 284 | 212 | 177 | 207 | 213 | 302 |
Hemoglobin (gm/L) | 145 | 127 | 108 | 99 | 103 | 108 |
Albumin (gm/L) | 31 | 30 | 28 | 23 | ND† | 27 |
Alanine aminotransferase (U/L) | 1017 | 1520 | 693 | 277 | ND | 81 |
Aspartate aminotransferase (U/L) | 852 | 998 | 116 | 61 | ND | 55 |
Lactate dehydrogenase (U/L) | 1579 | ND | 380 | 281 | 288 | 533 |
Serum creatinine (mg/dL) | 1.4 | 1.1 | 1 | 0.9 | 0.8 | 0.8 |
Estimated creatinine clearance (mL/min) | 74 | 96 | 107 | 117 | 131 | 131 |
Fibrinogen (mg/dL) | 472 | ND | 309 | 464 | 625 | 534 |
D-dimer (μg/mL FEU) | 16.47 | >20 | >20 | 10.41 | 10.03 | 3.82 |
Serum ferritin (μg/L) | 23713 | ND | 4590 | 2430 | 2359 | 2416 |
Procalcitonin (ng/mL) | 0.29 | ND | 0.19 | 0.32 | 0.3 | ND |
High sensitivity C-reactive protein (mg/L) | 149.2 | ND | ND | ND | ND | 64 |
Imaging features | No acute pulmonary process | Bilateral pulmonary emboli; Patchy ground- glass bilateral infiltrates | Improved aeration | Minimally increased opacities | Patchy densities in the upper lobes | ND |
Despite escalating oxygen requirements, intubation was delayed as the patient was assessed to be stable. The patient was prescribed HCQ 400 mg, given as a single oral dose, and NAC intravenously at 75 mg/kg over 4 hours, then 35 mg/kg over 16 hours, followed by 17 mg/kg over 24 hours on Day 2. Prophylactic anticoagulation was started with subcutaneous heparin. An additional 200 mg dose of HCQ was given on Day 2. No cardiac arrhythmia was noticed with either dose of HCQ, with the highest measured corrected QT interval documented at 0.49 (0.36–0.44 seconds).
This patient initially experienced progressive clinical improvement; however, bilateral pulmonary embolism (PE) and right lower extremity popliteal deep venous thrombosis were diagnosed in the setting of persistently elevated D-dimer. A heparin infusion was started, and PE embolization was complicated by severe hypoxemia requiring mechanical ventilation. After three days of mechanical ventilation and catheter-directed thrombolysis, he was successfully extubated and transferred to a general medicine floor on Day 7. The patient was discharged home on Day 12 with stable vital signs, normalizing laboratory values, and on therapeutic anticoagulation with rivaroxaban. COVID-19 RT-PCR prior to discharge was negative.
COVID-19 infection is characterized by multisystem organ involvement as illustrated in the present case yet no universally accepted standard therapy is available. It is theorized that COVID-19 causes the human immune system to overcompensate in response to infection and inflict collateral damage on itself, as evidenced by the abnormalities in inflammatory markers11–13 COVID-19 also appears to increase the risk of thrombotic events14,15. Previous work has shown that HCQ and NAC can modulate the innate immune system7,8, as well as reduce hypercoagulability and inhibit thrombosis16,17. We recognize that HCQ has been associated with a higher risk of cardiac abnormalities and fatal heart rhythms18; however, our low-dose strategy allowed us to take advantage of its potential benefits and long half-life. NAC has been shown to be safe at doses up to 980 mg/kg over 48 hours when used for acetaminophen overdose10. Because of this, we theorized that the administration of HCQ and NAC would be well-tolerated and have favorable effects on patient outcomes.
After the patient above received HCQ/NAC, clinical improvement was observed, and laboratory reports followed a similar pattern. Interestingly, use of low-dose HCQ in combination with intravenous NAC appeared to positively influence this patient’s clinical course. HCQ, with its lysosomal activity and impact on TLR-9, and NAC, with its anti-inflammatory activity via NF-κβ modulation, antioxidant activity, and glutathione replenishment, may provide a therapeutic combination capable of enhancing the activity of the innate immune system to combat viral invasion.
Early therapeutic intervention with modulators of the innate immune system such as HCQ (low doses) and NAC, appear to mitigate the effects of multisystem organ dysfunction observed in COVID-19 positive patients. Avoidance of mechanical ventilation may represent a secondary benefit of this therapy. A randomized clinical trial is warranted to further evaluate the benefits of HCQ/NAC combination for COVID-19 treatment.
Written informed consent for publication of their clinical details was obtained from the patient.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the background of the case’s history and progression described in sufficient detail?
No
Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
No
Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
No
Is the case presented with sufficient detail to be useful for other practitioners?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Internal medicines with interest in gastroenterology, hepatology and infectious diseases
Is the background of the case’s history and progression described in sufficient detail?
No
Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
No
Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
No
Is the case presented with sufficient detail to be useful for other practitioners?
Partly
References
1. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. University of Oxford. 2020. Reference SourceCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Pulmonary and critical care medicine; Infectious diseases
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 2 (revision) 24 Aug 20 |
read | ||
Version 1 02 Jun 20 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)